Core - Monoclonal Antibody

核心-单克隆抗体

• 批准号: 7746372
• 负责人: James A. DeCaprio
• 金额: $ 12.06万
• 依托单位: DANA-FARBER CANCER INST
• 依托单位国家: 美国
• 资助国家: 美国
• 起止时间: 至
• 项目状态: 未结题
• 来源: https://reporter.nih.gov/project-details/7746372
• 关键词: Accounting; Agar; Animals; Antibodies; Antibody Formation; Antigens; Bacteria; Baculoviruses; Basic Science; Cancer Center; Cancer Center Support Grant; Cell Culture Techniques; Charge; Clinical Protocols; Clinical Research; Clinical Trials; Clone Cells; Cloning; Collection; Consultations; Dana-Farber Cancer Institute; Data; Data Quality; Databases; Diagnosis; Disease; Drug toxicity; Ensure; Enzyme-Linked Immunosorbent Assay; Equipment; Eukaryotic Cell; Fee-for-Service Plans; Fees; Flow Cytometry; Hand; Human Resources; Hybridomas; Immune; Immunization; Immunofluorescence Immunologic; Immunoglobulin Class Switching; Immunoglobulin G; Immunoglobulins; Immunoprecipitation; Individual; Institution; Investigational Drugs; Keyhole Limpet Hemocyanin; Laboratories; Location; Lymph Node Dissections; Methods; Minority; Mission; Monitor; Monoclonal Antibodies; Multiple Myeloma; Mus; Mycoplasma; Oligonucleotides; Organization administrative structures; Patients; Peptides; Preparation; Price; Procedures; Process; Production; Proteins; Protocols documentation; Quality Control; Reagent; Recombinant Proteins; Records; Research Ethics Committees; Research Personnel; Research Support; Review Committee; Schedule; Scientist; Screening Result; Screening procedure; Serotyping; Serum; Services; Source; Splenectomy; Staging; Surrogate Markers; System; Testing; Time; Training; Vendor; Western Blotting; Woman; animal care; animal facility; base; clinical application; cost; design; discount; drug discovery; drug distribution; expression cloning; flexibility; interest; member; novel; protocol development; response; success; synthetic peptide; vector; Accounting; Agar; Animals; Antibodies; Antibody Formation; Antigens; Bacteria; Baculoviruses; Basic Science; Cancer Center; Cancer Center Support Grant; Cell Culture Techniques; Charge; Clinical Protocols; Clinical Research; Clinical Trials; Clone Cells; Cloning; Collection; Consultations; Dana-Farber Cancer Institute; Data; Data Quality; Databases; Diagnosis; Disease; Drug toxicity; Ensure; Enzyme-Linked Immunosorbent Assay; Equipment; Eukaryotic Cell; Fee-for-Service Plans; Fees; Flow Cytometry; Hand; Human Resources; Hybridomas; Immune; Immunization; Immunofluorescence Immunologic; Immunoglobulin Class Switching; Immunoglobulin G; Immunoglobulins; Immunoprecipitation; Individual; Institution; Investigational Drugs; Keyhole Limpet Hemocyanin; Laboratories; Location; Lymph Node Dissections; Methods; Minority; Mission; Monitor; Monoclonal Antibodies; Multiple Myeloma; Mus; Mycoplasma; Oligonucleotides; Organization administrative structures; Patients; Peptides; Preparation; Price; Procedures; Process; Production; Proteins; Protocols documentation; Quality Control; Reagent; Recombinant Proteins; Records; Research Ethics Committees; Research Personnel; Research Support; Review Committee; Schedule; Scientist; Screening Result; Screening procedure; Serotyping; Serum; Services; Source; Splenectomy; Staging; Surrogate Markers; System; Testing; Time; Training; Vendor; Western Blotting; Woman; animal care; animal facility; base; clinical application; cost; design; discount; drug discovery; drug distribution; expression cloning; flexibility; interest; member; novel; protocol development; response; success; synthetic peptide; vector

The Monoclonal Antibody Core is a DF/HCC core that was approved by the CSC in May 2004. The mission of the Monoclonal Antibody Core (MAC) is to produce novel monoclonal antibodies that are directed against antigens of interest to DF/HCC scientists. These monoclonal antibodies may be useful for basic research, drug discovery and clinical applications including diagnosis, surrogate markers for disease status, response to therapy or drug toxicity. This customized service is not available at other DF/HCC institutions.

单克隆抗体核心是CSC在2004年5月批准的DF/HCC核心。 单克隆抗体核心（MAC）的任务是产生新型的单克隆抗体 针对DF/HCC科学家感兴趣的抗原。这些单克隆抗体可能很有用 在基础研究中，药物发现和临床应用，包括诊断，替代标记 疾病状况，对治疗或药物毒性的反应。此定制服务在其他 DF/HCC机构。